American Capital commits $212 million to acquire Cambridge Major Laboratories

Private equity firm American Capital (Nasdaq: ACAS) says that it has committed $212 million in the buyout of USA-based Cambridge Major Laboratories, a global provider of complex chemistry-based outsourcing services to the pharmaceutical and biotechnology industries.

CML expands American Capital's portfolio of health care products and services companies, which have aggregate revenues of over $600 million. American Capital's investment took the form of debt and preferred and common equity.

Based in Germantown, Wisconsin, CML is an active pharmaceutical ingredient (API) development and manufacturing organization serving a broad customer base of pharmaceutical, biotech and generic drug companies. The company operates from Food and Drug Administration-inspected facilities in the USA and Europe. In 2012, the company developed and supplied over 100 APIs for drugs in the early and mid-stages of development and 14 APIs for drugs that are commercially available. The products CML manufactures span a wide range of therapeutic categories from cancer to neurology to rare genetic diseases.